Comparison of the use of 5-fluorouracil and bevacizumab in primary trabeculectomy: Results at 1year

Clinical and Experimental Ophthalmology

Volumn 40, Issue 4, 2012, Pages

  Jurkowska Dudzińska, Justyna ^a   Kosior Jarecka, Ewa ^a   Zarnowski, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

5 fluorouracil; Bevacizumab; Glaucoma; Trabeculectomy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL;

AGED; ANTERIOR EYE CHAMBER DEPTH; ARTICLE; CATARACT; CELL COUNT; CONJUNCTIVAL LEAK; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GLAUCOMA; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; PSEUDOEXFOLIATIVE GLAUCOMA; TENON CYST; TRABECULECTOMY; VISUAL ACUITY; VISUAL FIELD;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES; COMBINED MODALITY THERAPY; CONJUNCTIVA; EXFOLIATION SYNDROME; FEMALE; FLUOROURACIL; GLAUCOMA, OPEN-ANGLE; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; MALE; PROSPECTIVE STUDIES; TONOMETRY, OCULAR; TRABECULECTOMY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84862547793     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2011.02608.x     Document Type: Article

References (39)

1. Cairns JE. Trabeculectomy: preliminary report of a new method. Am J Ophthalmol 1968; 66: 673-9.
2. Addicks EM, Quigley HA, Green WR etal. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983; 101: 795- 808.
3. National Collaborating Centre for Acute Care. Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. London: The Royal College of Surgeons of England, 2009.
4. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003; 48: 314-46.
5. CAT-152 0102 Trabeculectomy Study Group. A phase III study of subconjunctival human anti-transforming growth factor beta (2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 2007; 114: 1822-30.
6. Keyt BA, Nguyen HV, Berleau LT. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor - selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996; 271: 5638-46.
7. Carmeliet P, Ferreira V, Breier G. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-9.
8. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
9. Avery RL, Pieramici DJ, Rabena MD etal. Intravitreal bevacizumab (Avastin) for neovascular age - related macular degeneration. Ophthalmology 2006; 113: 363-72.
10. Avery RL, Pearlman J, Pieramici DJ etal. Intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-715.
11. Papathanassiou M, Theodossiadis PG, Liarakos VS etal. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008; 145: 424-31.
12. Bahar I, Kaiserman I, McAllum P etal. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008; 27: 142-7.
13. Wells AP, Crowston JG, Marks J etal. A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma 2004; 13: 454-60.
14. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 2007; 39: 121-2.
15. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006; 37: 144-6.
16. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 2006; 37: 148-50.
17. Grisanti S, Biester S, Peters S etal. The Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142: 158-60.
18. Sothornwit N. Intravitreal bevacizumab for Ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thai 2008; 91 (Suppl. 1): S162-5.
19. Grewal DS, Rajeev J, Kumar H etal. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy. A pilot study. Ophthalmology 2008; 115: 2141-5.
20. Yorston D, Khaw PT. A randomised trial of the effect of intraoperative 5-FU on the outcome of trabeculectomy in east Africa. Br J Ophthalmol 2001; 85: 1028-30.
21. Wong T, Khaw P, Aung T etal. The Singapore 5-fluorouracil trabeculectomy study: effects on intraocular pressure control and disease progression at 3years. Ophthalmology 2009; 116: 175-84.
22. O'Brien C, Schwartz B, Takamoto T etal. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol 1991; 111: 491-500.
23. WuDunn O, Cantor LB, Palanca-Capistrano AM. A prospective randomized trial comparing intraoperative 5-flourouracil versus mitomycin C in primary trabeculectomy. Am J Ophthalmol 2002; 134: 521-8.
24. Poulsen EJ, Allingham RR. Characteristics and risk factors of infections after glaucoma filtering surgery. J Glaucoma 2000; 9: 438-43.
25. Law SK, Nguyen AM, Coleman AL etal. Severe loss of central vision in patients with advanced glaucoma undergoing trabeculectomy. Arch Ophthalmol 2007; 125: 1044-50.
26. Jampel H. Trabeculectomy: more effective at causing cataract surgery than lowering intraocular pressure? Ophthalmology 2009; 116: 173-4.
27. Kim CS, Yim JH, Lee EK etal. Changes in corneal endothelial cell density and morphology after Ahmed glaucoma valve implantation during the first year of follow up. Clin Experiment Ophthalmol 2008; 36: 142-7.
28. Hau S, Barton K. Corneal complications of glaucoma surgery. Curr Opin Ophthalmol 2009; 20: 131-6.
29. Lattanzio FA, Sheppard JD, Allen RC etal. Do injections of 5-fluorouracil after trabeculectomy have toxic effects on the anterior segment? J Ocul Pharmacol Ther 2005; 21: 223-35.
30. Cui LJ, Sun NX, Li XH etal. Subconjunctival sustained release 5-fluorouracil for glaucoma filtration surgery. Acta Pharmacol Sin 2008; 29: 1021-8.
31. Dreyer EB, Chaturvedi N, Zurakowski D. Effect of mitomycin C and fluorouracil-supplemented trabeculectomies on the anterior segment. Arch Ophthalmol 1995; 113: 578-80.
32. Mietz H, Roters S, Krieglstein GK etal. Bullous keratopathy as a complication of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1284-7.
33. Kim JH, Kim C, Kim JH etal. Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. Neurotoxicology 2008; 29: 1131-5.
34. Yoeruek E, Spitzer MS, Tatar O etal. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007; 26: 977-82.
35. Yoeruek E, Ziemssen F, Henke-Fahle S etal. Tuebingen Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008; 86: 322-8.
36. Wong J, Wang N, Miller JW etal. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 1994; 58: 439-51.
37. Kano MR, Morishita Y, Iwata C etal. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFR beta signaling. J Cell Sci 2005; 118: 3759-68.
38. Memarzadeh F, Varma R, Lin L etal. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009; 50: 3233-7.
39. Zarnowski T, Tulidowicz-Bielak M. Topical bevacizumab is efficacious in the early bleb failure after trabeculectomy. Acta Ophthalmol 2009; 87: e605-6.